Cargando…
Nuclear Export Inhibition for Pancreatic Cancer Therapy
Pancreatic cancer is a deadly disease that is resistant to most available therapeutics. Pancreatic cancer to date has no effective drugs that could enhance the survival of patients once their disease has metastasized. There is a need for the identification of novel actionable drug targets in this un...
Autores principales: | Muqbil, Irfana, Azmi, Asfar S., Mohammad, Ramzi M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5977111/ https://www.ncbi.nlm.nih.gov/pubmed/29735942 http://dx.doi.org/10.3390/cancers10050138 |
Ejemplares similares
-
The Role of microRNAs in the Diagnosis and Treatment of Pancreatic Adenocarcinoma
por: Diab, Maria, et al.
Publicado: (2016) -
Cancer cachexia research: coming of age
por: Muqbil, Irfana, et al.
Publicado: (2023) -
Progress in Nanotechnology Based Approaches to Enhance the Potential of Chemopreventive Agents
por: Muqbil, Irfana, et al.
Publicado: (2011) -
Targeting the Nuclear Export Protein XPO1/CRM1 Reverses Epithelial to Mesenchymal Transition
por: Azmi, Asfar S., et al.
Publicado: (2015) -
DNA-Methylation-Caused Downregulation of miR-30 Contributes to the High Expression of XPO1 and the Aggressive Growth of Tumors in Pancreatic Ductal Adenocarcinoma
por: Azmi, Asfar S., et al.
Publicado: (2019)